ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

PEPG PepGen Inc

14,49
0,59 (4,24%)
02 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
PepGen Inc PEPG NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,59 4,24% 14,49 22:00:49
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
14,00 13,41 14,59 14,49 13,90
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
13.3.202421:05GLOBEPepGen to Participate in Upcoming Investor Conferences
13.3.202412:00GLOBEPepGen Receives U.S. FDA Orphan Drug and Rare Pediatric..
06.3.202422:23EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
06.3.202422:01GLOBEPepGen Reports Fourth Quarter and Full Year 2023 Financial..
06.3.202422:00EDGAR2Form 8-K - Current report
04.3.202413:27EDGAR2Form 8-K - Current report
04.3.202413:00GLOBEPepGen Announces Clearance of CTA by UK Medicines &..
01.3.202423:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202423:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202423:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.2.202414:00EDGAR2Form 8-K - Current report
20.2.202414:00GLOBEPepGen Receives U.S. FDA Fast Track Designation for..
07.2.202422:55EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07.2.202413:36EDGAR2Form 8-K - Current report
07.2.202413:30GLOBEPepGen Announces Pricing of $80.1 Million Underwritten..
17.1.202414:00EDGAR2Form 8-K - Current report
17.1.202413:00GLOBEMary Beth DeLena Joins PepGen as General Counsel and..
08.1.202413:00EDGAR2Form 8-K - Current report
08.1.202413:00GLOBEPepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase..
18.12.202314:00EDGAR2Form 8-K - Current report
18.12.202314:00GLOBEPepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1..
15.11.202314:00EDGAR2Form 8-K - Current report
15.11.202314:00GLOBEPepGen Announces Appointment of Howard Mayer, M.D. to Board..
08.11.202314:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.11.202314:00EDGAR2Form 8-K - Current report
08.11.202314:00GLOBEPepGen Reports Third Quarter 2023 Financial Results and..
12.10.202313:52DJNFDA Lifts Hold on PepGen's New Drug Application for..
12.10.202313:05EDGAR2Form 8-K - Current report
12.10.202313:00GLOBEPepGen Inc. Announces FDA has Lifted the Clinical Hold on..
27.9.202322:16GLOBEPepGen Announces Upcoming Presentations at the 28th Annual..
06.9.202322:06EDGAR2Form 8-K - Current report
06.9.202322:05GLOBEPepGen Inc. Announces Clearance of CTA by Health Canada to..
06.9.202314:16EDGAR2Form 8-K - Current report
06.9.202314:00GLOBEPepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting..
01.9.202314:00GLOBEPepGen Announces Presentations at the 2023 Myotonic..
08.8.202314:49EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08.8.202314:27EDGAR2Form 8-K - Current report
08.8.202314:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.8.202314:15EDGAR2Form 8-K - Current report
08.8.202314:15GLOBEPepGen Reports Second Quarter 2023 Financial Results and..
13.6.202323:07DJNPepGen Withdraws Guidance on Launch of Study for Muscle..
13.6.202322:05GLOBEPepGen Inc. Provides Update on Planned Initiation of Phase 1..
30.5.202323:24DJNPepGen Shares Tumble 18.4% After FDA Issues Hold Notice on..
30.5.202322:05GLOBEPepGen Inc. Announces Clinical Hold in the U.S. on IND..
18.5.202313:00GLOBEPepGen Announces Clearance by Health Canada of CTA for..
11.5.202313:00GLOBEPepGen Reports First Quarter 2023 Financial Results and..
04.5.202314:00GLOBEPepGen to Participate in the Bank of America Securities 2023..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock